EX-8.1 4 dp21743_ex0801.htm EXHIBIT 8.1
 
Exhibit 8.1
 

 
At December 31, 2010
 
Country
 
Percentage of voting
share capital held (1)
 
Principal activity
UK
      
AstraZeneca UK Limited
England
100
Research and development, manufacturing, marketing
AstraZeneca Treasury Limited
England
100
Treasury
Continental Europe
      
NV AstraZeneca SA
Belgium
100
Marketing
AstraZeneca Dunkerque Production SCS
France
95
Manufacturing
AstraZeneca SAS
France
100
Research, manufacturing, marketing
Novexel SA
France
100
Research
AstraZeneca GmbH
Germany
100
Development, manufacturing, marketing
AstraZeneca Holding GmbH
Germany
100
Manufacturing, marketing
AstraZeneca SpA
Italy
100
Marketing
AstraZeneca Farmaceutica Spain SA
Spain
100
Marketing
AstraZeneca AB
Sweden
100
Research and development, manufacturing, marketing
AstraZeneca BV
The Netherlands
100
Marketing
The Americas
      
AstraZeneca Canada Inc.
Canada
100
Research, marketing
AZ Reinsurance Limited
Cayman Islands
100
Insurance and reinsurance underwriting
IPR Pharmaceuticals Inc.
Puerto Rico
100
Development, manufacturing, marketing
AstraZeneca LP
US
99
Research and development, manufacturing, marketing
AstraZeneca Pharmaceuticals LP
US
100
Research and development, manufacturing, marketing
Zeneca Holdings Inc.
US
100
Manufacturing, marketing
MedImmune, LLC
US
100
Research and development, manufacturing, marketing
Asia, Africa & Australasia
      
AstraZeneca Pty Limited
Australia
100
Development, manufacturing, marketing
AstraZeneca Pharmaceuticals Co., Limited
China
100
Research and development, manufacturing, marketing
AstraZeneca KK
Japan
80
Manufacturing, marketing
 
 
(1) All shares are held indirectly.
 

 
 
The companies and other entities listed above are those whose results or financial position principally affected the figures shown in the Financial Statements of AstraZeneca PLC and its subsidiaries (the “Group”).  A full list of subsidiaries, joint ventures and associates will be annexed to AstraZeneca PLC’s next annual return filed with the Registrar of Companies.  The country of registration or incorporation is stated alongside each company. The accounting year ends of subsidiaries and associates are December 31, except for Aptium Oncology, Inc. which, owing to local conditions and to avoid undue delay in the preparation of the Financial Statements, is November 30.  The Company operates through 254 subsidiaries worldwide.  Products are manufactured in 16 countries worldwide and are sold in over 100 countries.  The Group Financial Statements consolidate the Financial Statements of the Company and its subsidiaries at December 31, 2010.